BUZZ-Altimmune up on addition to Nasdaq Biotech index

Reuters12-19

** Drug developer Altimmune's ALT.O shares rise ~2% to $8.05 premarket

** Company says its shares will be added to Nasdaq Biotechnology index .NBI before market opens on Dec. 23

** Company currently testing pemvidutide for treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH)

** Avg rating of brokerages covering Altimmune stock is "buy"; median PT $24 - LSEG

** As of last close, company's shares have fallen 29.8% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492736441?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492736441","market":"us","top_or_hot":-1,"title":"BUZZ-Altimmune up on addition to Nasdaq Biotech index","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Altimmune up on addition to Nasdaq Biotech index</title></head><body><p>** Drug developer Altimmune's <span>ALT.O</span> shares rise ~2% to $8.05 premarket</p><p>** Company says its shares will be <span>added</span> to Nasdaq Biotechnology index <span>.NBI</span> before market opens on Dec. 23</p><p>** Company currently testing pemvidutide for treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH)</p><p>** Avg rating of brokerages covering Altimmune stock is \"buy\"; median PT $24 - LSEG</p><p>** As of last close, company's shares have fallen 29.8% YTD</p><p>(Reporting by Kamal Choudhury in Bengaluru)</p><p>((Kamal<a href=\"https://laohu8.com/S/02403\">.C</a>houdhury@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Altimmune up on addition to Nasdaq Biotech index</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Altimmune up on addition to Nasdaq Biotech index\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 21:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK13R:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Altimmune up on addition to Nasdaq Biotech index** Drug developer Altimmune's ALT.O shares rise ~2% to $8.05 premarket** Company says its shares will be added to Nasdaq Biotechnology index .NBI ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK13R:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALT","symbol_name":"Altimmune, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK13R:1","article_id":"2492736441","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492736441","pubTimestamp":1734616422,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Altimmune up on addition to Nasdaq Biotech index** Drug developer Altimmune's ALT.O shares rise ~2% to $8.05 premarket** Company says its shares will be added to Nasdaq Biotechnology index .NBI before market opens on Dec. 23** Company currently testing pemvidutide for treatment of obesity and metabolic dysfunction-associated steatohepatitis ** Avg rating of brokerages covering Altimmune stock is \"buy\"; median PT $24 - LSEG** As of last close, company's shares have fallen 29.8% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALT":"Altimmune, Inc.","BK4599":"减肥药","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4139":"生物科技"},"translate_title":"BUZZ-Altimmune加入纳斯达克生物技术指数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"BUZZ-Altimmune up on addition to Nasdaq Biotech index** Drug developer Altimmune's ALT.O shares rise ~2% to $8.05 premarket** Company says its shares will be added to Nasdaq Biotechnology index .NBI before market opens on Dec. 23** Company currently testing pemvidutide for treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH)** Avg rating of brokerages covering Altimmune stock is \"buy\"; median PT $24 - LSEG** As of last close, company's shares have fallen 29.8% YTD(Reporting by Kamal Choudhury in Bengaluru)((Kamal.Choudhury@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492736441"}